Allison S. Harney

Albert Einstein College of Medicine — United States

Biochemistry, Genetics and Molecular Biology · Life Sciences

20h-index3.0kcitations207works0.32yr avg

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Protein Tyrosine Phosphatases(64), RNA modifications and cancer(58), Biochemical and Molecular Research(49), Cancer Immunotherapy and Biomarkers(28), Pancreatic and Hepatic Oncology Research(26)

Publications207 total

Table S5 from SHP2 Inhibition Sensitizes Diverse Oncogene-Addicted Solid Tumors to Re-treatment with Targeted Therapy

2025Open Access

Table S6 from SHP2 Inhibition Sensitizes Diverse Oncogene-Addicted Solid Tumors to Re-treatment with Targeted Therapy

2025Open Access

Figure S4 from SHP2 Inhibition Sensitizes Diverse Oncogene-Addicted Solid Tumors to Re-treatment with Targeted Therapy

2025Open Access

Supplementary Methods from SHP2 Inhibition Sensitizes Diverse Oncogene-Addicted Solid Tumors to Re-treatment with Targeted Therapy

2025Open Access

Figure S1 from SHP2 Inhibition Sensitizes Diverse Oncogene-Addicted Solid Tumors to Re-treatment with Targeted Therapy

2025Open Access

Table S7 from SHP2 Inhibition Sensitizes Diverse Oncogene-Addicted Solid Tumors to Re-treatment with Targeted Therapy

2025Open Access

Table S4 from SHP2 Inhibition Sensitizes Diverse Oncogene-Addicted Solid Tumors to Re-treatment with Targeted Therapy

2025Open Access

Table S2 from SHP2 Inhibition Sensitizes Diverse Oncogene-Addicted Solid Tumors to Re-treatment with Targeted Therapy

2025Open Access

Table S8 from SHP2 Inhibition Sensitizes Diverse Oncogene-Addicted Solid Tumors to Re-treatment with Targeted Therapy

2025Open Access

Figure S2 from SHP2 Inhibition Sensitizes Diverse Oncogene-Addicted Solid Tumors to Re-treatment with Targeted Therapy

2025Open Access

Table S1 from SHP2 Inhibition Sensitizes Diverse Oncogene-Addicted Solid Tumors to Re-treatment with Targeted Therapy

2025Open Access

Table S3 from SHP2 Inhibition Sensitizes Diverse Oncogene-Addicted Solid Tumors to Re-treatment with Targeted Therapy

2025Open Access

Table S9 from SHP2 Inhibition Sensitizes Diverse Oncogene-Addicted Solid Tumors to Re-treatment with Targeted Therapy

2025Open Access

Figure S7 from SHP2 Inhibition Sensitizes Diverse Oncogene-Addicted Solid Tumors to Re-treatment with Targeted Therapy

2025Open Access

Figure S5 from SHP2 Inhibition Sensitizes Diverse Oncogene-Addicted Solid Tumors to Re-treatment with Targeted Therapy

2025Open Access

Figure S6 from SHP2 Inhibition Sensitizes Diverse Oncogene-Addicted Solid Tumors to Re-treatment with Targeted Therapy

2025Open Access

Figure S3 from SHP2 Inhibition Sensitizes Diverse Oncogene-Addicted Solid Tumors to Re-treatment with Targeted Therapy

2025Open Access

Targeting CSF-1 signaling between tumor cells and macrophages at TMEM doorways inhibits breast cancer dissemination

4 cited

Oncogene·2025· 4 citedOpen Access

Table 3 from Longitudinal Genomic Analysis to Fine-tune Targeted Therapy: Results of the Phase II LOGIC 2 Trial in Patients with BRAFV600-Mutant Metastatic Melanoma

2025Open Access

Figure 2 from Longitudinal Genomic Analysis to Fine-tune Targeted Therapy: Results of the Phase II LOGIC 2 Trial in Patients with BRAFV600-Mutant Metastatic Melanoma

2025Open Access

page 1 of 11Next →

Frequent Co-authors

John S. Condeelis(19), David Entenberg(17), Yarong Wang(13), Melissa L. Johnson(13), S. Michael Rothenberg(13), Maja H. Oktay(11), Micaela B. Reddy(11), Alexander Drilon(10), Timothy A. Yap(10), Shirish M. Gadgeel(10), Dale Nepert(10), Thomas J. Meade(9), Manish R. Sharma(9), Gang Feng(9), Mohamed Elsayed(9), Adam W. Cook(9), Christina E. Wong(9), Ronald J. Hinklin(9), Yutong Jiang(9), Eric N. Brown(9)